SEC Form 4 · accession 0001179110-16-018539
HALOZYME THERAPEUTICS, INC. · HALO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Helen Torley
Officer — President and CEO · Director
Period of report
Feb 3, 2016
Accepted (ET)
Feb 4, 2016 · 4:17 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001159036
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common StockF1 | $8.11 | Feb 3, 2016 | A | 376,569 | A | Feb 3, 2017 | Feb 3, 2026 | Common Stock | 376,569 | 376,569 | D |
| Restricted Stock UnitsF2 | $0.00 | Feb 3, 2016 | A | 221,948 | A | Feb 3, 2017 | Feb 3, 2026 | Common Stock | 221,948 | 221,948 | D |
Explanation of responses
- F1This option vests one-fourth on such date and then 1/48 monthly thereafter.
- F2This award vests one-fourth on such date and then one-fourth on each anniversary thereafter.